The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients

Lin, Richard J.; Michaud, Laure; Lobaugh, Stephanie; Nakajima, Reiko; Mauguen, Audrey; Elko, Theresa A; Ruiz, Josel D.; Maloy, Molly; Sauter, Craig S.; Dahi, Parastoo B.; Perales, Miguel-Ángel; Shah, Gunjan L.; Flores, Nerea Castillo; Sanchez-Escamilla, Míriam; Tomas, Ana Alarcón; Segundo, Lucrecia Yáñez San; Cho, Christina; Politikos, Ioannis; Kim, Soo Jung; Korc‐Grodzicki, Beatriz; Devlin, Sean M.; Scordo, Michael; Schöder, Heiko; Giralt, Sergío; Hamlin, Paul A.

doi:10.1080/10428194.2020.1742909

Cited by 14 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This diminution continues but less strongly until the end of first-line treatment. The reduction of SMA and SMI and consequent sarcopenia gain during the course of treatment was already demonstrated by other studies [ 10 , 11 , 12 , 13 ]. Compared to these studies where the rate of sarcopenia at baseline ranged from 27% to 55%, the rate of sarcopenia in our population was higher with 66% at baseline.…”

Section: Discussionsupporting

confidence: 64%

“…This is due to the advanced age (>65 years) of our patients. The only paper specific to older lymphoma [ 12 ] reported a rate of sarcopenia of 55%, but they included many lymphoma variants (only eight HL) and the age criterion of inclusion was superior to 50 years, lower than us. For these reasons, a direct comparison with other studies seems to be difficult and excessive.…”

Section: Discussionmentioning

confidence: 79%

“…However, a parameter not well evaluated is the evolution of body composition during treatment in oncological patients. Initial studies reported body composition changes occurring after therapy in lymphoma, such as hematopoietic cell transplantation [ 10 , 11 , 12 ] or systemic therapy (chemotherapy) [ 13 ], but with controversial results. Thus, the first aim of this retrospective study was to describe the longitudinal body changes in terms of muscle and adipose areas measured by baseline, interim, and end of treatment [ 18 F]FDG PET/CT in elderly patients affected by HL undergoing chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Longitudinal Body Composition Changes Detected by [18F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma

Albano

Dondi

Treglia

et al. 2022

Cancers

View full text Add to dashboard Cite

The aim of this retrospective study was to investigate the longitudinal body changes in terms of muscle and adipose areas and their prognostic role in elderly (>65 years) patients affected by Hodgkin lymphoma (HL). Skeletal muscle area (SMA), skeletal muscle index (SMI), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), intramuscular adipose tissue (IMAT), and total dispose tissue (TAT) were measured using the computed tomography (CT) of fluorine-18-fluorodeoxyglucose positron emission tomography/CT ([18F]FDG PET/CT) in 88 patients who undertook baseline, interim (after two cycles of chemotherapy), and end-of-treatment (after 6 cycles of chemotherapy) PET/CT scans. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were measured at pre-treatment PET/CT. Metabolic response applying Deauville score was evaluated at interim and end-of-treatment PET/CT. Survival curves, such as progression free survival (PFS) and overall survival (OS), were calculated for the whole population. Fifty-eight (66%) patients had sarcopenia at baseline and sarcopenia rate increased at interim scan with 68 (77%) cases and at end-of-treatment scan with 73 (83%) cases. Muscular areas (SMA and SMI) declined significantly during the treatment (p < 0.001), decreasing from baseline by 5% and 7% at interim and end-of-treatment evaluation, respectively. Instead, VAT, SAT, IMAT, and TAT increased significantly over this time (p < 0.001). Sarcopenia was significantly related with comprehensive geriatric assessment. PET/CT response at interim and end-of-treatment, MTV, TLG, and baseline sarcopenia were independent prognostic factors for PFS. Instead, metabolic response at interim and end-of-treatment PET, baseline sarcopenia, ΔSMI at interim, and ΔSMI at end-of-treatment for OS were independent prognostic factors.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Longitudinal Body Composition Changes Detected by [18F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma

Albano

Dondi

Treglia

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In the JBI tool for cohort studies, category seven assesses the validity of the survival outcomes, and we found that only two studies 14 , 15 clearly reported that survival was reported based on official national death records. Four studies 16 , 17 , 18 , 19 did not provide a statement on how death was reported, and this ambiguity introduced bias. Quality assessment of these studies is presented in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis

Anabtawi,

Pasala,

Grimshaw

et al. 2024

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundLow skeletal muscle mass (LSMM) and/or, function associated with an increased risk of treatment‐related toxicities and inferior overall survival (OS) among adults with solid malignancies. However, the association between LSMM and treatment‐related toxicities among adults with haematologic malignancies remains unclear.MethodsUsing a pre‐published protocol (CRD42020197814), we searched seven bibliographic databases from inception to 08/2021 for studies reporting the impact of LSMM among adults ≥18 years with a known haematologic malignancy. The primary outcome of interest was OS, and secondary outcomes included progression free survival (PFS) and non‐relapse mortality (NRM). These effect sizes were quantified in terms of hazards ratio (HR) along with 95% confidence interval (CI) and pooled across studies using a DerSimonian–Laird random‐effects model. Heterogeneity was assessed using the Cochran's Q and the I2 statistic. All hypothesis testing was two‐sided with an alpha of 0.05.ResultsOf 3791 studies screened, we identified 20 studies involving 3468 patients with a mean age of 60 years; 44% were female and the most common malignancy was diffuse large B‐cell lymphoma (42%). Most studies measured muscle mass using single slice computed tomography imaging at the L3 level. The presence of LSMM was associated with worse OS (pooled HR = 1.81, 95% CI = 1.48–2.22, P < 0.001) with moderate heterogeneity (Cochran's Q, I2 = 60.4%), PFS (pooled HR = 1.61, 95% CI = 1.28–2.02, P < 0.001) with moderate heterogeneity (Cochran's Q, I2 = 66.0%). Similarly, LSMM was associated with worse NRM (HR = 1.72, 95% CI = 1.34–2.22, P < 0.001) with little evidence of heterogeneity (Cochran's Q, I2 = 0.0%).ConclusionsLSMM is associated with worse survival outcomes among adults with haematologic malignancies. Further research into understanding the underlying mechanism of this association and mitigating the negative effects of LSMM among adults with haematologic malignancies is needed.

show abstract

“…Among hematologic malignancies, sarcopenia has been mostly evaluated in patients with lymphoma, and to a lesser extent in patients with leukemia. While some studies have found sarcopenia to be associated with inferior outcomes with chemoimmunotherapy [ 8 – 13 ] and transplant [ 14 – 17 ], others have shown no prognostic impact [ 18 ], or even a protective role of sarcopenia [ 19 ]. These discordant results are, at least in part, explained by variability in the populations and subgroups studied and differences in the thresholds used to define sarcopenia [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Muscle and fat composition in patients with newly diagnosed multiple myeloma

Abdallah,

Nagayama,

Takahashi

et al. 2023

Blood Cancer J.

View full text Add to dashboard Cite

Measures of muscle and adipose tissue mass have been associated with outcomes in several malignancies, but studies in multiple myeloma (MM) are inconsistent. The aim of this study was to evaluate the association between muscle and fat areas and radiodensity, and overall survival (OS) in patients with newly diagnosed MM. We included 341 patients diagnosed with MM from 2010–2019 who had an 18F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis. A cross-sectional image at the third lumbar vertebrae was segmented into muscle and fat components. Median follow up was 5.7 years. There was no association between sarcopenia and baseline disease characteristics or OS. Low muscle radiodensity was associated with higher disease stage, anemia, and renal failure. OS was 5.6 vs. 9.0 years in patients with muscle radiodensity in the lower vs. middle/upper tertiles, respectively (P = 0.02). High subcutaneous adipose tissue (SAT) radiodensity was associated with higher stage, anemia, thrombocytopenia, hypercalcemia, renal failure, and high LDH. OS was 5.4 years vs. not reached in patients with SAT radiodensity in the upper vs. middle/lower tertiles, respectively (P = 0.001). In conclusion, sarcopenia was not associated with OS in MM patients. High SAT radiodensity and low muscle radiodensity were associated with advanced disease stage and adverse laboratory characteristics.

show abstract

The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients

Cited by 14 publications

References 40 publications

Longitudinal Body Composition Changes Detected by [18F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma

Longitudinal Body Composition Changes Detected by [18F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma

Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta‐analysis

Muscle and fat composition in patients with newly diagnosed multiple myeloma

Contact Info

Product

Resources

About